The U.S. market for breast-disease detection and diagnostic technology will reach $590 million in sales in 2002, up 17% from the $506 million recorded in 2001, according to a report issued by market research firm Medtech Insight. Breast biopsy will continue to represent the largest segment in product sales for open and percutaneous procedures, generating $180.3 million in sales in 2002.
The second largest segment, conventional mammography, will produce $107.5 million in product sales, with pharmacogenetic and prognostic testing to reach almost $96 million, according to the Tustin, CA-based firm. In its report, U.S. Markets for Breast Disease Detection and Diagnostic Technologies, 2001-2011, Medtech said that breast disease will increase as the over-40 U.S. population spikes by 10 million people from 2002 to 2006.
Technology improvements, such as digital mammography and computer-aided detection, will result in earlier identification of more breast cancers and suspicious lesions; this dynamic will affect the entire array of post-screening medical interventions, said Medtech president and CEO Sharon O'Reilly.
Medtech also predicts a growing role for early-detection technologies such as 3-D ultrasound and thermography. Electrical impedance breast-imaging systems will climb to almost $130 million in sales over the next decade, O'Reilly said. In addition, emerging prognostic/pharmacogenetic testing approaches may soon help direct physicians to the most effective therapy for each woman, she said.
By AuntMinnie.com staff writers
November 14, 2002
Related Reading
Medicare boosts outpatient mammography and colonoscopy payment rates, November 5, 2002
Innovative programs cut through mammography's crisis, October 17, 2002
Multiple-reading protocol bolsters interpretation for non-mammographers, September 6, 2002
Ultrasonography improves cancer screening of dense breasts, September 20, 2002
Radiologists slammed by malpractice insurance crisis, April 23, 2002
Copyright © 2002 AuntMinnie.com
